These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 36030492)
1. Clinical implication and immunological landscape analyses of ANLN in pan-cancer: A new target for cancer research. Zhang L; Wei Y; He Y; Wang X; Huang Z; Sun L; Chen J; Zhu Q; Zhou X Cancer Med; 2023 Feb; 12(4):4907-4920. PubMed ID: 36030492 [TBL] [Abstract][Full Text] [Related]
2. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures. Zhang X; Wang Y; A G; Qu C; Chen J Front Immunol; 2021; 12():721030. PubMed ID: 34531868 [TBL] [Abstract][Full Text] [Related]
3. Pan-cancer analysis of the prognostic and immunological role of ANLN: An onco-immunological biomarker. Liu K; Cui L; Li C; Tang C; Niu Y; Hao J; Bu Y; Chen B Front Genet; 2022; 13():922472. PubMed ID: 35991576 [TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2. Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y Front Immunol; 2023; 14():1155182. PubMed ID: 37275857 [TBL] [Abstract][Full Text] [Related]
5. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers. Wang N; Zhu L; Wang L; Shen Z; Huang X Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736 [TBL] [Abstract][Full Text] [Related]
6. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer. Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444 [TBL] [Abstract][Full Text] [Related]
7. Pan-Cancer Analysis Reveals the Multidimensional Expression and Prognostic and Immunologic Roles of Zhang S; Xiong H; Yang J; Yuan X Front Mol Biosci; 2021; 8():792154. PubMed ID: 35155565 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis of ANLN in Human Tumors: A Prognostic Biomarker Associated with Cancer Immunity. Zhang X; Li L; Huang S; Liao W; Li J; Huang Z; Huang Y; Lian Y Oxid Med Cell Longev; 2022; 2022():5322929. PubMed ID: 35340220 [TBL] [Abstract][Full Text] [Related]
9. RelB is a potential molecular biomarker for immunotherapy in human pan-cancer. Wu J; Yu X; Zhu H; Chen P; Liu T; Yin R; Qiang Y; Xu L Front Mol Biosci; 2023; 10():1178446. PubMed ID: 37388242 [No Abstract] [Full Text] [Related]
10. Pan-Cancer Analysis Revealed Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J J Oncol; 2022; 2022():3477148. PubMed ID: 35069733 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value and immunological role of PDCD1 gene in pan-cancer. Miao Y; Wang J; Li Q; Quan W; Wang Y; Li C; Wu J; Mi D Int Immunopharmacol; 2020 Dec; 89(Pt B):107080. PubMed ID: 33069926 [TBL] [Abstract][Full Text] [Related]
12. Prognostic and Immunological Roles of Cell Cycle Regulator CDCA5 in Human Solid Tumors. He J; Zhou X; Wang X; Zhang Q; Zhang L; Wang T; Zhu W; Liu P; Zhu M Int J Gen Med; 2022; 15():8257-8274. PubMed ID: 36438022 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity. Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive analyses reveal the carcinogenic and immunological roles of ANLN in human cancers. Shi Y; Ma X; Wang M; Lan S; Jian H; Wang Y; Wei Q; Zhong F Cancer Cell Int; 2022 May; 22(1):188. PubMed ID: 35568883 [TBL] [Abstract][Full Text] [Related]
15. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression. Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X Front Oncol; 2022; 12():927988. PubMed ID: 35756681 [TBL] [Abstract][Full Text] [Related]
16. ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer. Magnusson K; Gremel G; Rydén L; Pontén V; Uhlén M; Dimberg A; Jirström K; Pontén F BMC Cancer; 2016 Nov; 16(1):904. PubMed ID: 27863473 [TBL] [Abstract][Full Text] [Related]
17. A prognostic and immunological analysis of 7B-containing Kelch structural domain (KLHDC7B) in pan-cancer: a potential target for immunotherapy and survival. Ding J; Ji X; Liu L; Chen DZ; Luo N; Yu XT; Guo F J Cancer Res Clin Oncol; 2023 Aug; 149(10):7857-7876. PubMed ID: 37039902 [TBL] [Abstract][Full Text] [Related]
18. Multi-omics analysis of the oncogenic value of copper Metabolism-Related protein COMMD2 in human cancers. Tai P; Wang Z; Chen X; Chen A; Gong L; Cheng Y; Cao K Cancer Med; 2023 May; 12(10):11941-11959. PubMed ID: 36205192 [TBL] [Abstract][Full Text] [Related]
19. A pan-cancer analysis to determine the prognostic analysis and immune infiltration of HSPA5. Zhu RK; Zhang W; Zhang YX; Hui Z; Wang XW Curr Cancer Drug Targets; 2023 May; ():. PubMed ID: 37157205 [TBL] [Abstract][Full Text] [Related]
20. Comprehensive bioinformatics analysis reveals the prognostic value, predictive value, and immunological roles of ANLN in human cancers. Cui Z; Mo J; Song P; Wang L; Wang R; Cheng F; Wang L; Zou F; Guan X; Zheng N; Yang X; Wang W Front Genet; 2022; 13():1000339. PubMed ID: 36199577 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]